1 The 5-hydroxytryptamine (5-HT,)-like agonist, sumatriptan, is highly efficient in the relief of migraine headache and its accompanying symptoms. 2 Experimental evidence has indicated that its site of action may be on the cranial vessels or on the trigeminal innervation of the cranium, or both, since sumatriptan does not pass the blood-brain barrier easily under normal circumstances. It is, however, not clear whether the blood-brain barrier is normal or abnormal during a migraine attack. 3 In this study, single unit activity and trigeminal somatosensory evoked potentials in central trigeminal neurones were monitored during electrical stimulation of the superior sagittal sinus. 4 Intravenous administration of sumatriptan (100 ig kg-') did not alter trigeminal evoked activity unless the permeability of the blood-brain barrier had been increased by infusion of an hyperosmolar mannitol solution. After blood-brain barrier disruption, sumatriptan decreased the peak-to-peak amplitude of evoked potentials by 40 ± 6% and the probability of firing of single units by 30 ± 9%. Mannitol infusions alone in control animals caused no changes in evoked potentials or single unit activity. 5 The data suggest that in normal circumstances sumatriptan does not have sufficient access to trigeminal neurones to alter their function.
Introduction
Migraine is well recognized clinically although its fundamental pathophysiology is unknown. Based on both clinical and experimental data we have proposed a unifying hypothesis integrating both the central nervous system structures, such as the trigeminal nucleus caudalis, and the trigeminal innervation of the meninges and cranial vessels (Goadsby et al., 1991a) . The synthesis and clinical trial of the novel 5-hydroxytryptamine (5-HT,-like) agonist, sumatriptan, has provided both an important addition to clinical practice and a valuable research tool. The site of action of sumatriptan is of particular interest as it may provide a direction for further drug development and an understanding of at least part of the mechanism of migraine.
It has been proposed that the site of action of sumtriptan is at cranial arteries as a highly selective vasoconstrictor , or in the periphery at the trigeminovascular innervation of the cranium (Markowitz et al., 1988) . Both hypotheses for a peripheral site of action are consistent with the fact that under normal circumstances sumatriptan cannot penetrate the blood-brain barrier in substantial amounts .
In a series of well conceived experiments it has been shown that whereas intravenous administration of sumatriptan neither effects frontal cortex levels of 5-HT (Sleight et al., 1990) nor pial vessel diameter (Connor et al., 1992) , local injection of the drug can alter both 5-HT levels in brain and pial vessel diameter. Since it has been shown that vasodilatation of cranial vessels may not necessarily be a sufficient stimulus to activate trigeminal neurones (Kaube et al., 1992) , vasoconstriction may, therefore, not be the only mechanism responsible for the clinical efficacy of the drug in migraine (Goadsby et al., 1991b; Ferrari, 1991) . Given that other drugs with similar pharmacological actions that are also useful in migraine, such as dihydroergotamine, have access to ' Author for correspondence. central nervous system binding sites (Goadsby & Gundlach, 1991) it is of interest that sumatriptan directly applied by iontophoresis to trigeminal neurones inhibits single unit activity linked to sagittal sinus stimulation in 20% of tested units (Boers, 1989) . The prospect of a central locus of action of sumatriptan would then stand as a third alternative to explain its action.
In order to investigate the effects of systemically administered sumatriptan on the central processing of trigeminal noxious stimuli, we combined the electrophysiological model of sagittal sinus stimulation and recording from the dorsolateral cervical spinal cord, that we have previously characterized (Lambert et al., 1988; Goadsby & Zagami, 1991) , with hyperosmolar infusions to disrupt the blood-brain barrier. Mannitol was used as an hyperosmolar agent because of its low toxicity and the well-documented time course of its action (Cosolo et al., 1989) . As a marker for increased permeability of the blood-brain barrier we chose Evans Blue which can be detected in small quantities by fluorescence microscopy techniques.
Methods
Eleven female cats weighing 2.7 ± 0.2 kg were anaesthetized initially with 1.5% halothane and then a-chloralose (60 mg kg-', i.p.) and prepared for physiological monitoring. The femoral artery and vein were cannulated in order to measure blood pressure and heart rate and provide access for drug administration, respectively. Cardiovascular parameters and pupillary reaction to noxious pinching of the forepaw were used to determine the need for supplementary anaesthesia. The animals were endotracheally intubated, ventilated with 40% oxygen and paralyzed after the surgical procedures with repeated doses of gallamine triethiodide (6 mg kg-', i.v., as required). Body temperature and end-expiratory CO2 were monitored and maintained within physiological limits.
Surgery
After mounting in a stereotactic frame, a circular midline craniotomy (2 cm in diameter) and C1/C2-laminectomy were performed for access to the superior sagittal sinus (SSS) and the recording site in the C2 spinal cord. Possible artefacts from arterial pulsation and respiratory movement were reduced by: bilateral pneumothoraces, suspension of the thoracic spinal processes, clamping of the Cl lateral spinal processes and covering the cervical spinal cord with a layer of agar gel. At the recording site the pia mater was carefully removed to facilitate the insertion of the electrode. The dura mater and falx adjacent to the SSS were dissected over 10mm and the sinus suspended over bipolar platinum hook electrodes. To prevent dehydration and,for electrical insulation against the cortex, a paraffin bath was built with a dam of dental acrylic around the craniotomy and a small polyethylene sheet was inserted under the SSS.
Stimulation
To activate trigeminal primary afferents, the SSS was stimulated with a Grass S88 stimulator driving a stimulus isolation unit (SIUSA; 150 V, 250 As duration, 0.3 s-').
Tungsten-in-glass microelectrodes (tip length/diameter: 50/ 15 Am, impedance: <200 kQ) were lowered into the dorsolateral spinal cord 4-5 mm caudal to the mid-point of the C2-rootlets between 500 and 1500 mm below the surface with a hydraulic micropositioner ( This component was then subtracted from all previous recordings prior to determining the peak-to-peak amplitudes. Data were compared by the Wilcoxon matched pairs signed ranks test (Siegel, 1956) and assessed for significance at the P < 0.05 level.
Blood-brain barrier integrity
In preliminary experiments carried out to determine the parameters for the hyperosmolar infusion scheme, animals were injected with 2% Evans Blue (50 mg kg-') followed in some animals by mannitol infusions and perfused with saline and 10% formaldehyde through the thoracic descending aorta. The spinal cords were removed. Spinal cord levels Cl to C3 were sectioned on a cryo-microtome at 50 Lm, and inspected under a fluorescent microscope at 365 nm to evaluate the presence of Evans Blue qualitatively as an indicator for an increased permeability of the blood-brain barrier.
Results
Physiological parameters of the eleven animals included in the analysis were normal ( Table 1 ). The studies with Evans Blue confirmed that the mannitol infusions that were used increased blood-brain barrier permeability in the upper cervical spinal cord. Systemic arterial blood pressure was increased (14 ± 5 mmHg) after the injection of sumatriptan for 5 to 15 min while mannitol infusions also caused a transient elevation of blood pressure (19 ± 3 mmHg) lasting up to 30min.
Electrophysiological data
Electrical stimulation of the superior sagittal sinus elicited linked electrophysiological responses in the dorsolateral C2 spinal cord. Baseline peak-to-peak amplitudes for trigeminal somatosensory evoked potentials were 438 ± 161 liV in Group 1 animals and 451 ± 188 ytV in Group 2. The latencies for the peak of the first component were 9.8 ± 0.4 ms and 9.3 ± 0.4 ms, respectively. The baseline probability of firing for linked single units in the dorsolateral area was 0.44 ± 0.06 with a latency of 6.9 ± 0.6 ms for the fastest component in the post stimulus histogram. Infusions with mannitol alone (group 1) had no effect on the field potentials (3 ± 10%; Figure 1 ). Sumatriptan alone (group 2) led only to a small transient increase in peak-to-peak amplitudes of trigeminal evoked potentials that was maximal after 30 min. After disruption of the blood-brain barrier with mannitol the evoked responses were significantly reduced by 40 ± 6% (P = 0.03, n = 6; Figure 2 ). The effects on single units were similar. Only the combination of intravenous sumatriptan and disruption of the blood-brain barrier led to a significant inhibition (Figure 3 ) in the probability of firing of single units (30 ± 9%). There was no consistent effect of sumatriptan or mannitol administration alone on the latencies of evoked potentials or single units. siderations apply equally to the control and treated groups g '); (c) evoked potentials 30nm) after infusion of 12.5% and are, therefore, unlikely to be the reason for the results as (90min after sumatriptan).
described.
As the inhibition of the electrophysiological responses only occurred after the administration of both sumatriptan and mannitol, it is most likely that the disruption of the bloodsion brain barrier is pivotal in facilitating the inhibitory effect of sumatriptan. The decrease in firing after mannitol infusion lata demonstrate that sumatriptan can interact with could have been caused by physico-mechanical changes in the nsmission of nociceptive input in central trigeminal neural tissue induced by the blood pressure changes or the ,s suggesting inhibitory modulation of synapses at the increased intravascular volume resulting in the loss of the order neurone if entry of the drug into the central monitored single units. This could not explain why this effect system has been facilitated. The time interval would only occur in animals that had been pretreated with i the injection of sumatriptan and the hyperosmolar sumatriptan. The recording with long tipped, low impedance z was 60 min and was long enough to allow the tungsten-in-glass microelectrodes enabled us to record field ary changes in blood pressure and field potential potentials and single unit activity together. However, the low ides to recover before the next intervention. Since spatial discrimination of such electrodes often leads to the iptan has a plasma half-life of 2-4 h, enough active recruitment of more than one single unit action potential. In and was still available after 1 h when the mannitol the case of firing clusters our analysis software did not allow n was given.
us to distinguish between cell body and axonal action potenitial to the interpretation of these data is that the tials. (Humphrey et al., 1990) . In a study in rat it has been shown that intravenous injection of sumatriptan did not alter brain production of 5-HT while a local injection, that would bypass the blood-brain barrier, reduced brain 5-HT levels (Sleight et al., 1990) . Furthermore, sumatriptan has no effect on isolated pial vessels unless it is injected directly around those vessels when it acts as a vasoconstrictor, again suggesting that the blood-brain barrier must be passed for a significant action to be seen (Connor et al., 1992) . The data reported here extend this concept more directly into the brain regions likely to be involved in mi- sumatriptan on cranial vessels , its inhibitory effect on the release of calcitonin gene-related peptide from trigeminal nerve terminals (Goadsby & Edvinsson, 1993) and tracers will reveal more about the role of supraspinal and spinal structures in the pathophysiology of migraine. Poststimulus histograms of single unit activity (average of These data suggest that the status of the blood-brain barrier titive recordings) after electrical stimulation of the superior in migraine must be studied if the action and site of action of sinus recorded from the dorsolateral C2 spinal cord. (a) antimigraine compounds is to be understood since these recording; (b) recording 30 min after injection of sumatripdrugs have significant actions in the central nervous system if I sg kg-'; (c) single unit activity 30 min after infusion of access to the brain is possible.
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nannitol (90 min after sumatriptan).
multiple single unit firing to identify which or how many units stopped firing after the pharmacological intervention. However, it was a consistent finding that the total probability of firing computed for the whole post-stimulus interval was markedly decreased only after the administration of sumatriptan and mannitol. 
